ArQule Shares Outstanding 2006-2019 | ARQL

ArQule shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ArQule Annual Shares Outstanding
(Millions of Shares)
2018 99
2017 75
2016 70
2015 63
2014 63
2013 62
2012 60
2011 53
2010 45
2009 44
2008 44
2007 40
2006 36
2005 35
ArQule Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 120
Q2 2019 110
Q1 2019 109
Q4 2018 99
Q3 2018 107
Q2 2018 101
Q1 2018 87
Q4 2017 75
Q3 2017 72
Q2 2017 71
Q1 2017 71
Q4 2016 70
Q3 2016 71
Q2 2016 71
Q1 2016 65
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 63
Q1 2014 63
Q4 2013 62
Q3 2013 63
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 62
Q2 2012 61
Q1 2012 54
Q4 2011 53
Q3 2011 54
Q2 2011 53
Q1 2011 51
Q4 2010 45
Q3 2010 45
Q2 2010 45
Q1 2010 44
Q4 2009 44
Q3 2009 44
Q2 2009 44
Q1 2009 44
Q4 2008 44
Q3 2008 44
Q2 2008 44
Q1 2008 44
Q4 2007 40
Q3 2007 44
Q2 2007 37
Q1 2007 36
Q4 2006 36
Q3 2006 36
Q2 2006 35
Q1 2006 35
Q4 2005 35
Q3 2005 35
Q2 2005 35
Q1 2005 33
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.945B $0.026B
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.
Stock Name Country Market Cap PE Ratio
Takeda Pharmaceutical (TAK) Japan $62.374B 9.86
Zoetis (ZTS) United States $55.370B 33.12
Astellas Pharma (ALPMY) Japan $31.354B 15.66
Eisai (ESALY) Japan $18.833B 36.31
Merck (MKGAF) Germany $15.199B 20.74
Grifols, S.A (GRFS) Spain $14.885B 18.99
UCB SA (UCBJF) Belgium $14.669B 0.00
Neurocrine Biosciences (NBIX) United States $10.118B 477.70
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
IPSEN SA ADR (IPSEY) France $8.953B 0.00
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.638B 0.00
Ionis Pharmaceuticals (IONS) United States $8.129B 16.46
Jazz Pharmaceuticals (JAZZ) Ireland $7.571B 9.67
Sage Therapeutics (SAGE) United States $7.295B 0.00
Catalent (CTLT) United States $7.185B 29.23
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.214B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
STADA ARZNEIMI (STDAF) Germany $5.375B 0.00
Hypermarcas (HYPMY) Brazil $5.178B 18.61
Arrowhead Pharmaceuticals (ARWR) United States $4.598B 105.43
United Therapeutics (UTHR) United States $3.929B 0.00
Nektar Therapeutics (NKTR) United States $3.418B 0.00
FibroGen (FGEN) United States $3.052B 89.69
Evotec AG (EVTCY) Germany $3.051B 49.93
Taro Pharmaceutical Industries (TARO) Israel $2.937B 10.73
PTC Therapeutics (PTCT) United States $2.633B 0.00
Portola Pharmaceuticals (PTLA) United States $2.091B 0.00
Xencor (XNCR) United States $2.040B 62.00
Zogenix (ZGNX) United States $2.005B 0.00
Tilray (TLRY) Canada $1.986B 0.00
Corcept Therapeutics (CORT) United States $1.888B 22.94
Heron Therapeutics (HRTX) United States $1.877B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.819B 58.00
Pacira Pharmaceuticals (PCRX) United States $1.777B 52.57
USANA Health Sciences (USNA) United States $1.561B 16.66
CLINIGEN GP (CLIGF) United Kingdom $1.244B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.221B 20.14
Radius Health (RDUS) United States $1.095B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.005B 0.00
Karyopharm Therapeutics (KPTI) United States $0.964B 0.00
Endo (ENDP) Ireland $0.943B 1.73
Spectrum Pharmaceuticals (SPPI) United States $0.907B 0.00
Aerie Pharmaceuticals (AERI) United States $0.844B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.811B 5.53
TherapeuticsMD (TXMD) United States $0.746B 0.00
Organogenesis Holdings (ORGO) United States $0.740B 0.00
Collegium Pharmaceutical (COLL) United States $0.613B 0.00
Flexion Therapeutics (FLXN) United States $0.610B 0.00
Concordia (CXRXF) Canada $0.552B 0.00
Translate Bio (TBIO) United States $0.550B 0.00
ChemoCentryx (CCXI) United States $0.508B 0.00
ImmunoGen (IMGN) United States $0.490B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.485B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.484B 58.75
Aptorum Group (APM) Hong Kong, SAR China $0.455B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.445B 0.00
OptiNose (OPTN) United States $0.413B 0.00
Dermira (DERM) United States $0.411B 0.00
Siga Technologies (SIGA) United States $0.406B 9.28
BioSpecifics Technologies Corp (BSTC) United States $0.389B 16.76
Ardelyx (ARDX) United States $0.387B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.384B 0.00
Akebia Therapeutics (AKBA) United States $0.383B 0.00
Indivior (INVVY) United States $0.378B 1.37
Lannett Co Inc (LCI) United States $0.376B 4.37
Recro Pharma (REPH) United States $0.375B 0.00
Innate Pharma SA (IPHYF) France $0.372B 0.00
DURECT (DRRX) United States $0.367B 0.00
Harpoon Therapeutics (HARP) United States $0.325B 0.00
GlycoMimetics (GLYC) United States $0.282B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.278B 0.00
Molecular Templates (MTEM) United States $0.259B 0.00
Xeris Pharmaceuticals (XERS) United States $0.215B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.211B 0.00
KalVista Pharmaceuticals (KALV) United States $0.195B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.186B 0.00
Nature's Sunshine Products (NATR) United States $0.185B 31.83
Calithera Biosciences (CALA) United States $0.181B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.175B 0.00
Jounce Therapeutics (JNCE) United States $0.175B 2.34
La Jolla Pharmaceutical (LJPC) United States $0.164B 0.00
Concert Pharmaceuticals (CNCE) United States $0.164B 0.00
Taiwan Liposome (TLC) Taiwan $0.162B 0.00
Aquestive Therapeutics (AQST) United States $0.154B 0.00
CV Sciences (CVSI) United States $0.142B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.138B 0.00
Redhill Biopharma (RDHL) Israel $0.135B 0.00
MEI Pharma (MEIP) United States $0.133B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.129B 0.00
Ocular Therapeutix (OCUL) United States $0.128B 0.00
CannTrust Holdings (CTST) Canada $0.126B 0.00
IMV INC (IMV) Canada $0.122B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.118B 0.00
Cardiome Pharma (CORV) Canada $0.111B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.093B 0.00
MediWound (MDWD) Israel $0.083B 0.00
Majesco Entertainment (PTE) United States $0.079B 0.00
Neos Therapeutics (NEOS) United States $0.078B 0.00
Otonomy (OTIC) United States $0.077B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.076B 22.64
Aclaris Therapeutics (ACRS) United States $0.074B 0.00
SCYNEXIS (SCYX) United States $0.068B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.067B 0.00
Generex Biotechnology (GNBT) United States $0.065B 0.00
Natural Alternatives (NAII) United States $0.064B 15.96
Opiant Pharmaceuticals (OPNT) United States $0.063B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.062B 0.00
Champions Oncology (CSBR) United States $0.060B 0.00
Genocea Biosciences (GNCA) United States $0.059B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.057B 0.00
Medicure (MCUJF) Canada $0.057B 0.00
Infinity Pharmaceuticals (INFI) United States $0.056B 0.00
Pharmaxis (PXSLY) Australia $0.055B 0.00
Novan (NOVN) United States $0.055B 0.00
RENEURON GP (RNUGF) United Kingdom $0.054B 0.00
IntelGenx Technologies (IGXT) Canada $0.053B 0.00
Nivalis Therapeutics (ALPN) United States $0.051B 0.00
Capnia (SLNO) United States $0.049B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.049B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.046B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.045B 0.00
ElectroCore (ECOR) United States $0.044B 0.00
CTI BioPharma (CTIC) United States $0.043B 0.00
Forward Pharma (FWP) Denmark $0.040B 0.00
Mannatechorporated (MTEX) United States $0.036B 0.00
Jaguar Animal Health (JAGX) United States $0.034B 0.00
Opexa Therapeutics (ACER) United States $0.032B 0.00
Bio-Path Holdings (BPTH) United States $0.031B 0.00
Iterum Therapeutics (ITRM) Ireland $0.030B 0.00
Biomerica (BMRA) United States $0.030B 0.00
Mast Therapeutics (SVRA) United States $0.029B 0.00
PharmAthene (ALT) United States $0.025B 0.00
China SXT Pharmaceuticals (SXTC) China $0.023B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Melinta Therapeutics (MLNT) United States $0.019B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.016B 0.00
Flex Pharma (SLRX) United States $0.015B 0.00
Heat Biologics (HTBX) United States $0.015B 0.00
Cyanotech (CYAN) United States $0.014B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Shineco (TYHT) China $0.013B 16.42
Regulus Therapeutics (RGLS) United States $0.013B 0.00
Lipocine (LPCN) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.009B 0.00
Vical (BBI) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
Achieve Life Sciences (ACHV) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
VAXART, INC (VXRT) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00
Onconova Therapeutics (ONTX) United States $0.002B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00